{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:53:57Z","timestamp":1793332437017,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["UID: 113547"],"award-info":[{"award-number":["UID: 113547"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001323","name":"Poliomyelitis Research Foundation","doi-asserted-by":"publisher","award":["17\/49"],"award-info":[{"award-number":["17\/49"]}],"id":[{"id":"10.13039\/501100001323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004513","name":"Harry Crossley Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001342","name":"Department of Science and Technology, Republic of South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Higher Education Department, next Generation of Programme"},{"name":"South African Research Chairs Initiative of the Department of Science and Innovation","award":["64751"],"award-info":[{"award-number":["64751"]}]},{"name":"South African Research Chairs Initiative of the Department of Science and Innovation","award":["64751"],"award-info":[{"award-number":["64751"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Integrase (IN) strand transfer inhibitor (INSTI), Dolutegravir (DTG), has been given the green light to form part of first-line combination antiretroviral therapy (cART) by the World Health Organization (WHO). DTG containing regimens have shown a high genetic barrier against HIV-1 isolates carrying specific resistance mutations when compared with other class of regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We evaluated the HIV-1 CRF02_AG IN gene sequences from Cameroon for the presence of resistance-associated mutations (RAMs) against INSTIs and naturally occurring polymorphisms (NOPs), using study sequences (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920) and (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009287) sequences data derived from HIV Los Alamos National Laboratory database. The possible impact of NOPs on protein structure caused by HIV-1 CRF02_AG variations was addressed within the context of a 3D model of the HIV-1 IN complex and interaction analysis was performed using PyMol to validate DTG binding to the Wild type and seven mutant structures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed 12.8% (37\/287) sequences to contain RAMs, with only 1.0% (3\/287) of the sequences having major INSTI RAMs: T66A, Q148H, R263K and N155H. Of these,11.8% (34\/287) of the sequences contained five different IN accessory mutations; namely Q95K, T97A, G149A, E157Q and D232N. NOPs occurred at a frequency of 66% on the central core domain (CCD) position, 44% on the C-terminal domain (CTD) position and 35% of the N-terminal domain (NTD) position. The interaction analysis revealed that DTG bound to DNA, 2MG ions and DDE motif residues for T66A, T97A, Q148H, N155H and R263K comparable to the WT structure. Except for accessory mutant structure E157Q, only one MG contact was made with DTG, while DTG had no MG ion contacts and no DDE motif residue contacts for structure D232N.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our analysis indicated that all RAM\u2019s that resulted in a change in the number of interactions with encompassing residues does not affect DTG binding, while accessory mutations E157Q and D232N could affect DTG binding leading to possible DTG resistance. However, further experimental validation is required to validate the in silico findings of our study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-06059-x","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T06:04:14Z","timestamp":1619157854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations"],"prefix":"10.1186","volume":"21","author":[{"given":"Sello Given","family":"Mikasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumbidzai","family":"Chitongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Mondide","family":"Ikomey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme Brendon","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1966-0212","authenticated-orcid":false,"given":"Ruben","family":"Cloete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"6059_CR1","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.meegid.2016.06.047","volume":"46","author":"Y-S Han","year":"2016","unstructured":"Han Y-S, Mespl\u00e8de T, Wainberg MA. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors. Infect Genet Evol. 2016;46:286\u201391.","journal-title":"Infect Genet Evol"},{"issue":"5","key":"6059_CR2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1089\/aid.2019.0264","volume":"36","author":"SG Mikasi","year":"2020","unstructured":"Mikasi SG, Gichana JO, Van der Walt C, Brado D, Obasa AE, Njenda D, et al. HIV-1 Integrase diversity and resistance-associated mutations and polymorphisms among Integrase Strand transfer inhibitor-naive HIV-1 patients from Cameroon. AIDS Res Hum Retrovir. 2020;36(5):450\u20135. https:\/\/doi.org\/10.1089\/aid.2019.0264.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"00","key":"6059_CR3","first-page":"1","volume":"00","author":"SG Mikasi","year":"2020","unstructured":"Mikasi SG, Isaacs D, Ikomey GM, Shimba H, Cloete R, Jacobs GB. HIV-1 drug resistance Mutation analyses of Cameroon-derived Integrase sequences. AIDS Res Hum Retrovir. 2020;00(00):1\u20133.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"9","key":"6059_CR4","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1128\/JCM.00602-09","volume":"47","author":"J Plantier","year":"2009","unstructured":"Plantier J, Djemai M, Leme V, Reggiani A, Leoz M, Burc L, et al. Census and analysis of persistent false-negative results in Serological diagnosis of human immunodeficiency virus type 1 group O infections. J Clin Microbiol. 2009;47(9):2906\u201311.","journal-title":"J Clin Microbiol"},{"issue":"12","key":"6059_CR5","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1089\/aid.2012.0058","volume":"28","author":"MF Oliveira","year":"2012","unstructured":"Oliveira MF, Ramalho DB, Abreu CM. Genetic diversity and naturally polymorphisms in HIV type 1 Integrase isolates from Maputo, Mozambique. AIDS Res Hum Retroviruses. 2012;28(12):1788\u201392.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"6059_CR6","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1186\/1742-4690-6-103","volume":"6","author":"T Bar-magen","year":"2009","unstructured":"Bar-magen T, Sloan RD, Faltenbacher VH, Donahue DA, Kuhl BD, Oliveira M, et al. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology. 2009;6:2048.","journal-title":"Retrovirology"},{"key":"6059_CR7","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1097\/QAD.0b013e32833cf265","volume":"24","author":"T Bar-magen","year":"2010","unstructured":"Bar-magen T, Donahue DA, Mcdonough EI, Kuhl D, Faltenbacher VH, Xu H, et al. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. Aids. 2010;24:2171\u20139.","journal-title":"Aids"},{"key":"6059_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0128310","volume":"10","author":"PK Quashie","year":"2015","unstructured":"Quashie PK, Han Y, Hassounah S, De TM. Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor. Plos one. 2015;10:1\u201318.","journal-title":"Plos one"},{"key":"6059_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1128\/AAC.00539-19","volume":"63","author":"K Theys","year":"2019","unstructured":"Theys K, Libin PJ, Van Laethem K, Abecasis AB. An evolutionary-based approach to quantify the genetic barrier to drug resistance in fast- evolving viruses: an application to HIV-1 subtypes and integrase inhibitors. Antimicrob Agents Chemother. 2019;63:8.","journal-title":"Antimicrob Agents Chemother"},{"key":"6059_CR10","first-page":"2016","volume":"2","author":"LE Bain","year":"2020","unstructured":"Bain LE, Nkoke C, Noubiap JJN. UNAIDS 90\u201390 \u2013 90 targets to end the AIDS epidemic by 2020 are not realistic: comment on \u201c Can the UNAIDS 90\u201390 \u2013 90 target be achieved ? A systematic analysis of national HIV treatment cascades\u201d. BMJ Global Health. 2020;2:2016\u20138.","journal-title":"BMJ Global Health"},{"issue":"December","key":"6059_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.18683\/germs.2017.1124","volume":"7","author":"GM Ikomey","year":"2017","unstructured":"Ikomey GM, Claire M, Assoumou O, Gichana JO, Njenda D. Original article observed HIV drug resistance associated mutations amongst na\u00efve immunocompetent children in Yaound\u00e9, Cameroon. Germs. 2017;7(December):178\u201385.","journal-title":"Germs"},{"key":"6059_CR12","doi-asserted-by":"publisher","unstructured":"Tchouwa GF, Eymard-Duvernay S, Cournil A, Lamare N, Serrano L, Butel C, et al. Prevalence of pretreatment HIV drug resistance in Cameroon following a nationally representative WHO survey. J Antimicrob Chemother 2018;73(9):2468\u20132474. Available from: https:\/\/doi.org\/10.1093\/jac\/dky221.","DOI":"10.1093\/jac\/dky221"},{"issue":"4","key":"6059_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/COH.0000000000000374","volume":"12","author":"JM Jacobson","year":"2017","unstructured":"Jacobson JM, Flexner CW. Universal antiretroviral regimens: thinking beyond one-pill-once-a-day. Curr Opin HIV AIDS. 2017;12(4):343\u201350. https:\/\/doi.org\/10.1097\/COH.0000000000000374.","journal-title":"Curr Opin HIV AIDS"},{"issue":"5","key":"6059_CR14","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3390\/ijms21051553","volume":"21","author":"A Acharya","year":"2020","unstructured":"Acharya A, Tagny CT, Mbanya D, Fonsah JY, Nchindap E, Kenmogne L, et al. Variability in HIV-1 Integrase gene and 3\u2032-Polypurine tract sequences in Cameroon clinical isolates, and implications for Integrase inhibitors efficacy. Int J Mol Sci. 2020;21(5):1553. https:\/\/doi.org\/10.3390\/ijms21051553.","journal-title":"Int J Mol Sci"},{"key":"6059_CR15","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing hiv infection. Recommendations for a public health approach","author":"WHO","year":"2019","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing hiv infection. Recommendations for a public health approach. 2nd ed: World Health Organization; 2019. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/208825\/%0A9789241549684%0A","edition":"2"},{"issue":"1","key":"6059_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1128\/AAC.03909-14","volume":"59","author":"T Yoshinaga","year":"2015","unstructured":"Yoshinaga T, Kobayashi M, Seki T, Miki S, Wakasa-morimoto C, Suyama-kagitani A. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother. 2015;59(1):397\u2013406.","journal-title":"Antimicrob Agents Chemother"},{"key":"6059_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1126\/science.287.5453.646","volume":"287","author":"DJ Hazuda","year":"2000","unstructured":"Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287:646\u201351.","journal-title":"Science"},{"key":"6059_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","volume":"98","author":"L Men\u00e9ndez-arias","year":"2013","unstructured":"Men\u00e9ndez-arias L. Molecular basis of human immunodeficiency virus type 1 drug resistance: Overview and recent developments. Antiviral Res. 2013;98:93\u2013120.","journal-title":"Antiviral Res"},{"issue":"4","key":"6059_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1124\/mol.111.073189","volume":"80","author":"S Hare","year":"2011","unstructured":"Hare S, Smith SJ, Me M, Jaxa-chamiec A, Pommier Y, Hughes SH, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S \/ GSK1349572). Mol Pharmacol. 2011;80(4):565\u201372.","journal-title":"Mol Pharmacol"},{"issue":"5","key":"6059_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1089\/aid.2019.0264","volume":"36","author":"SG Mikasi","year":"2020","unstructured":"Mikasi SG, Gichana JO, Walt C, Van Der Brado D, Obasa AE, Njenda D, et al. Transfer Inhibitor-Naive HIV-1 Patients from Cameroon. AIDS Res Hum Retroviruses. 2020;36(5):450\u20135.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"6059_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ijid.2005.11.006","volume":"11","author":"S Paraschiv","year":"2007","unstructured":"Paraschiv S, Otelea D, Dinu M, Maxim D, Tinischi M. Polymorphisms and resistance mutations in the protease and reverse transcriptase genes of HIV-1 F subtype Romanian strains. Int J Infect Dis. 2007;11:123\u20138.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"6059_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.00708-13","volume":"4","author":"RS Kantor","year":"2013","unstructured":"Kantor RS, Wrighton KC, Handley KM, Sharon I, Hug LA, Castelle CJ, et al. Small genomes and sparse metabolisms of sediment-associated bacteria from four candidate phyla. MBio. 2013;4(5):1\u201311.","journal-title":"MBio"},{"issue":"May","key":"6059_CR23","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/nar\/gky427","volume":"46","author":"A Waterhouse","year":"2018","unstructured":"Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL : homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46(May):296\u2013303.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"6059_CR24","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/pro.5560020916","volume":"2","author":"C Colovos","year":"1993","unstructured":"Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 1993;2(9):1511\u20139. https:\/\/doi.org\/10.1002\/pro.5560020916.","journal-title":"Protein Sci"},{"issue":"5016","key":"6059_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1126\/science.1853201","volume":"253","author":"JU Bowie","year":"1991","unstructured":"Bowie JU, L\u00fcthy R, Eisenberg D. A method to identify protein sequences that fold into a known three-dimensional structure. Science. 1991;253(5016):164\u201370. https:\/\/doi.org\/10.1126\/science.1853201.","journal-title":"Science"},{"issue":"4","key":"6059_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/BF00228148","volume":"8","author":"RA Laskowski","year":"1996","unstructured":"Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR. 1996;8(4):477\u201386. https:\/\/doi.org\/10.1007\/BF00228148.","journal-title":"J Biomol NMR"},{"key":"6059_CR27","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/jcc.20090","volume":"25","author":"C Oostenbrink","year":"2004","unstructured":"Oostenbrink C, Villa A, Mark AE, Gunsteren WF. A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS Force-Field Parameter sets 53A5 and 53A6. J Comput Chem. 2004;25:1656\u201376.","journal-title":"J Comput Chem"},{"issue":"10","key":"6059_CR28","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","volume":"31","author":"KJ Lepik","year":"2017","unstructured":"Lepik KJ, Harrigan PR, Yip B, Wang L, Robbins MA, Zhang WW, et al. Emergent drug resistance with integrase strand transfer inhibitor-based regimens. AIDS. 2017;31(10):1425\u201334. https:\/\/doi.org\/10.1097\/QAD.0000000000001494.","journal-title":"AIDS"},{"key":"6059_CR29","first-page":"1","volume":"11","author":"S Rhee","year":"2008","unstructured":"Rhee S, Liu TF, Kiuchi M, Zioni R, Gifford RJ, Holmes SP, et al. Natural variation of HIV-1 group M integrase : Implications for a new class of antiretroviral inhibitors. Retrovirology. 2008;11:1\u201311.","journal-title":"Retrovirology"},{"key":"6059_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12977-017-0360-7","volume":"14","author":"K Anstett","year":"2017","unstructured":"Anstett K, Brenner B, Mesplede T, Wainberg MA. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology. 2017;14:1\u201316.","journal-title":"Retrovirology"},{"key":"6059_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2018.01754","volume":"9","author":"L Rogers","year":"2018","unstructured":"Rogers L, Obasa AE, Jacobs GB, Sarafianos SG, S\u00f6nnerborg A, Neogi U, et al. Structural implications of genotypic variations in HIV-1 integrase from diverse subtypes. Front Microbiol. 2018;9:1\u20139.","journal-title":"Front Microbiol"},{"issue":"5","key":"6059_CR32","doi-asserted-by":"publisher","first-page":"e0223464","DOI":"10.1371\/journal.pone.0223464","volume":"15","author":"R Chitongo","year":"2020","unstructured":"Chitongo R, Obasa AE, Mikasi SG, Jacobs GB, Cloete R. Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding. PLoS One. 2020;15(5):e0223464. https:\/\/doi.org\/10.1371\/journal.pone.0223464.","journal-title":"PLoS One"},{"key":"6059_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0164619","volume":"11","author":"A Gupta","year":"2016","unstructured":"Gupta A, Juneja S, Vitoria M, Habiyambere V, Nguimfack D, Doherty M, et al. Projected uptake of new antiretroviral ( ARV ) medicines in adults in low- and middle- income countries : a forecast analysis 2015\u20132025. PLoS One. 2016;11:1\u201318.","journal-title":"PLoS One"},{"issue":"1","key":"6059_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4314\/ejhs.v30i1.6","volume":"30","author":"S Mabeya","year":"2020","unstructured":"Mabeya S, Nyamache A, Ngugi C, Nyerere A, Lihana R. Characterization of HIV-1 Integrase gene and Resistance associated mutations prior to roll out of Integrase inhibitors by Kenyan national HIV-treatment program in Kenya. Ethiop J Health Sci. 2020;30(1):37\u201344. https:\/\/doi.org\/10.4314\/ejhs.v30i1.6.","journal-title":"Ethiop J Health Sci"},{"issue":"6","key":"6059_CR35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1089\/aid.2020.0021","volume":"36","author":"S Masoud","year":"2020","unstructured":"Masoud S, Kamori D, Barabona G, Mahiti M, Sunguya B, Lyamuya E, et al. Circulating HIV-1 integrase genotypes in Tanzania: implication on the introduction of integrase inhibitors-based antiretroviral therapy regimen. AIDS Res Hum Retroviruses. 2020;36(6):539\u201343.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"6059_CR36","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3390\/v12090936","volume":"12","author":"D Isaacs","year":"2020","unstructured":"Isaacs D, Mikasi SG, Obasa AE, Ikomey GM. Structural comparison of diverse Hiv-1 subtypes using molecular modelling and docking analyses of integrase inhibitors. Viruses. 2020;12:936.","journal-title":"Viruses"},{"issue":"17","key":"6059_CR37","doi-asserted-by":"publisher","first-page":"9683","DOI":"10.1128\/JVI.00947-14","volume":"88","author":"SA Hassounah","year":"2014","unstructured":"Hassounah SA, Mespl\u00e8de T, Quashie PK, Oliveira M, Sandstrom PA, Wainberg A. Effect of HIV-1 Integrase resistance mutations when introduced into SIVmac239 on susceptibility to Integrase Strand transfer inhibitors. J Virol. 2014;88(17):9683\u201392. https:\/\/doi.org\/10.1128\/JVI.00947-14.","journal-title":"J Virol"},{"issue":"2","key":"6059_CR38","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/AAC.01209-10","volume":"55","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, et al. Kawauchi- Miki S, Taishi T, Kawasuji T, Johns BA, underwood MR, Garvey EP, Sato a FT. in vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55(2):813\u201321. https:\/\/doi.org\/10.1128\/AAC.01209-10.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"6059_CR39","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/cid\/cit697","volume":"58","author":"CB Hurt","year":"2014","unstructured":"Hurt CB, Sebastian J, Hicks CB, Eron JJ. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis. 2014;58(3):423\u201331. https:\/\/doi.org\/10.1093\/cid\/cit697.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"6059_CR40","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.1128\/AAC.00157-11","volume":"55","author":"KE Hightower","year":"2011","unstructured":"Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, et al. Dolutegravir (S\/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 2011;55(10):4552\u20139. https:\/\/doi.org\/10.1128\/AAC.00157-11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"6059_CR41","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1128\/AAC.02568-12","volume":"57","author":"ME Abram","year":"2013","unstructured":"Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, et al. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother. 2013;57(6):2654\u201363. https:\/\/doi.org\/10.1128\/AAC.02568-12.","journal-title":"Antimicrob Agents Chemother"},{"key":"6059_CR42","first-page":"232","volume-title":"HHS Public Access","author":"S Hare","year":"2010","unstructured":"Hare S, Gupta SS, Valkov E, Engelman A, Place N. HHS Public Access. 2010;464(7286):232\u2013236."},{"issue":"March","key":"6059_CR43","first-page":"1","volume":"11","author":"AE Obasa","year":"2020","unstructured":"Obasa AE, Mikasi SG, Brado D, Cloete R, Singh K, Neogi U, et al. Drug resistance mutations against protease, reverse transcriptase and integrase inhibitors in people living with HIV-1 receiving boosted protease inhibitors in South Africa. Front Microbiol. 2020;11(March):1\u20139.","journal-title":"Front Microbiol"},{"key":"6059_CR44","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1093\/jac\/dky005","volume":"92","author":"SC Inzaule","year":"2018","unstructured":"Inzaule SC, Hamers RL, Noguera-Julian M, Casadell\u00e0 M, Parera M, Rinke de Wit TF, et al. Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa. J Antimicrob Chemother. 2018;92:1167\u201372.","journal-title":"J Antimicrob Chemother"},{"key":"6059_CR45","first-page":"210","volume-title":"HHS Public Access","author":"CJ Villabona-arenas","year":"2015","unstructured":"Villabona-arenas CJ, Domyeum J, Mouacha F, Delaporte E, Peeters M, Mpoudi-Ngole E, et al. HHS Public Access; 2015. p. 210\u20136."},{"issue":"8","key":"6059_CR46","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/j.1469-0691.2010.03392.x","volume":"17","author":"J-Y Kim","year":"2011","unstructured":"Kim J-Y, Kim E-J, Choi J-Y, Kwon O-K, Kim GJ, Choi SY, et al. Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-na\u00efve patients with HIV\/AIDS in Korea. Clin Microbiol Infect. 2011;17(8):1155\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"6059_CR47","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1089\/aid.2013.0271","volume":"30","author":"T Kotaki","year":"2014","unstructured":"Kotaki T, Khairunisa SQ, Sukartiningrum SD, Witaningrum AM, Rusli M, Diansyah MN, et al. Detection of drug resistance-associated mutations in human immunodeficiency virus type 1 integrase derived from drug-naive individuals in Surabaya, Indonesia. AIDS Res Hum Retroviruses. 2014;30(5):489\u201392. https:\/\/doi.org\/10.1089\/aid.2013.0271.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"6059_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-017-0887-1","volume":"14","author":"K Meixenberger","year":"2017","unstructured":"Meixenberger K, Yousef KP, Smith MR, Somogyi S, Fiedler S, Bartmeyer B, et al. Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors. Virol J. 2017;14:1\u201313.","journal-title":"Virol J"},{"key":"6059_CR49","doi-asserted-by":"crossref","unstructured":"Tostevin A, White E, Dunn D, Croxford S, Delpech V, Williams I, et al. Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. HIV Med. 2017; Available from: http:\/\/www.scopus.com\/inward\/record.url?scp=84994415935&partnerID=8YFLogxK.","DOI":"10.1111\/hiv.12414"},{"issue":"413","key":"6059_CR50","first-page":"7","volume":"51","author":"CB Passaes","year":"2009","unstructured":"Passaes CB, Guimaraes ML, Fernandez SL, Lorete Rdos S, Teixeira SL, Fernandez JC, et al. Lack of primary mutations associated with Integrase inhibitors among HIV-1 subtypes B, C, and F Circulating in Brazil. JAIDS. 2009;51(413):7\u201312.","journal-title":"JAIDS"},{"key":"6059_CR51","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/infdis\/jis750","volume":"207","author":"JJ Eron","year":"2013","unstructured":"Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013;207:740\u20138.","journal-title":"J Infect Dis"},{"issue":"22","key":"6059_CR52","doi-asserted-by":"publisher","first-page":"11440","DOI":"10.1128\/JVI.01168-09","volume":"83","author":"S Fransen","year":"2009","unstructured":"Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M, et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol. 2009;83(22):11440\u20136.","journal-title":"J Virol"},{"key":"6059_CR53","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jac\/dkt316","volume":"69","author":"GL Melikian","year":"2014","unstructured":"Melikian GL, Rhee S, Varghese V, Porter D, White K, Taylor J, et al. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother. 2014;69:12\u201320.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"6059_CR54","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3851\/IMP3033","volume":"21","author":"LK Naeger","year":"2016","unstructured":"Naeger LK, Harrington P, Komatsu T, Deming D. Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients. Antivir Ther. 2016;21(6):481\u20138. https:\/\/doi.org\/10.3851\/IMP3033.","journal-title":"Antivir Ther"},{"key":"6059_CR55","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1093\/jac\/dkx511","volume":"73","author":"C Charpentier","year":"2018","unstructured":"Charpentier C, Malet I, Andre-garnier E, Storto A, Bocket L, Amiel C, et al. Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen. J Antimicrob Chemother. 2018;73:1039\u201344.","journal-title":"J Antimicrob Chemother"},{"key":"6059_CR56","doi-asserted-by":"publisher","unstructured":"Anstett K, Cutillas V, Fusco R, Mespl\u00e8de T, Wainberg MA. Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity. J Antimicrob Chemother 2016;71(8):2083\u20132088. Available from: https:\/\/doi.org\/10.1093\/jac\/dkw109.","DOI":"10.1093\/jac\/dkw109"},{"issue":"2","key":"6059_CR57","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1128\/JVI.01534-07","volume":"82","author":"K Shimura","year":"2008","unstructured":"Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303\/GS-9137). J Virol. 2008;82(2):764\u201374. https:\/\/doi.org\/10.1128\/JVI.01534-07.","journal-title":"J Virol"},{"key":"6059_CR58","doi-asserted-by":"publisher","unstructured":"Fun A, Van Baelen K, van Lelyveld SFL, Schipper PJ, Stuyver LJ, Wensing AMJ, et al. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity. J Antimicrob Chemother 2010;65(11):2300\u20132304. Available from: https:\/\/doi.org\/10.1093\/jac\/dkq319.","DOI":"10.1093\/jac\/dkq319"},{"issue":"9","key":"6059_CR59","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/infdis\/jir025","volume":"203","author":"J-L Blanco","year":"2011","unstructured":"Blanco J-L, Varghese V, Rhee S-Y, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis. 2011;203(9):1204\u201314. https:\/\/doi.org\/10.1093\/infdis\/jir025.","journal-title":"J Infect Dis"},{"issue":"3","key":"6059_CR60","doi-asserted-by":"publisher","first-page":"1194 LP","DOI":"10.1128\/AAC.00984-08","volume":"53","author":"GS Jones","year":"2009","unstructured":"Jones GS, Yu F, Zeynalzadegan A, Hesselgesser J, Chen X, Chen J, et al. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother. 2009;53(3):1194 LP\u20131203 Available from: http:\/\/aac.asm.org\/content\/53\/3\/1194.abstract.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"6059_CR61","doi-asserted-by":"publisher","first-page":"e00315","DOI":"10.1128\/AAC.00315-17","volume":"61","author":"A Hachiya","year":"2017","unstructured":"Hachiya A, Kirby KA, Ido Y, Shigemi U, Matsuda M, Okazaki R, et al. Impact of HIV-1 Integrase L74F and V75I mutations in a clinical isolate on resistance to second-generation Integrase Strand transfer inhibitors. Antimicrob Agents Chemother. 2017;61(8):e00315\u20137 Available from: http:\/\/aac.asm.org\/content\/61\/8\/e00315-17.abstract.","journal-title":"Antimicrob Agents Chemother"},{"key":"6059_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-015-0734-3","volume":"13","author":"A Mulu","year":"2015","unstructured":"Mulu A, Maier M, Liebert UG. Lack of integrase inhibitors associated resistance mutations among HIV - 1C isolates. J Transl Med. 2015;13:1\u20138.","journal-title":"J Transl Med"},{"issue":"4","key":"6059_CR63","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.drudis.2014.12.001","volume":"20","author":"Y Li","year":"2015","unstructured":"Li Y, Xuan S, Feng Y, Yan A. Targeting HIV-1 integrase with strand transfer inhibitors. Drug Discov Today. 2015;20(4):435\u201349. https:\/\/doi.org\/10.1016\/j.drudis.2014.12.001.","journal-title":"Drug Discov Today"},{"issue":"5","key":"6059_CR64","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.3390\/molecules15053048","volume":"15","author":"JF Mouscadet","year":"2010","unstructured":"Mouscadet JF, Desma\u00eble D. Chemistry and structure-activity relationship of the styrylquinoline-type HIV integrase inhibitors. Molecules. 2010;15(5):3048\u201378 Available from: https:\/\/europepmc.org\/articles\/PMC6263292.","journal-title":"Molecules"},{"issue":"1","key":"6059_CR65","first-page":"4","volume":"4","author":"MI Cai","year":"1997","unstructured":"Cai MI, Zheng RI, Caffrey M, Craigie R, Clore GM, Gronenborn AM. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat Struct Biol. 1997;4(1):4\u20135.","journal-title":"Nat Struct Biol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06059-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06059-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06059-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T11:15:57Z","timestamp":1686309357000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06059-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["6059"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06059-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-40608\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]},"assertion":[{"value":"3 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study form part of a broader study, for which the ethic was obtained from the Health Research Ethics Committee of Stellenbosch University (N14\/10\/130 and N15\/08\/071). The database sequences were conducted according to the ethical guidelines and principles of the international Declaration of Helsinki 2013, South African Guidelines for Good Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines for Research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"379"}}